Ablation vs medication for atrial fibrillation

In AF the upper chambers of the heart quiver chaotically, causing an irregular, often fast pulse, and increasing the risk of stroke. Treatment has three separate jobs: prevent stroke, control symptoms, and treat any underlying causes such as high blood pressure, alcohol excess, sleep apnoea or thyroid disease.

Medication and ablation address the second job, symptoms. They do not replace the first, which is why anticoagulant tablets are often needed whichever route is taken.

Rate-control drugs such as beta-blockers or certain calcium channel blockers slow the heart so that fast AF causes fewer symptoms. This suits many older people and those with persistent AF who feel acceptably well. Rhythm-control drugs, called anti-arrhythmics, aim to keep the heart in normal rhythm, and may be combined with an electrical cardioversion to restart it.

Drugs are non-invasive and flexible but may cause side effects, need monitoring and often lose effect over time. Some are unsuitable in people with certain heart conditions or kidney problems.

During catheter ablation, thin tubes are guided through a vein to the heart. Energy, either radiofrequency heat or freezing (cryoablation), creates small scars around the pulmonary veins where many AF triggers originate, electrically isolating them. It is usually done under sedation or general anaesthetic and typically needs an overnight stay or a short admission.

Benefits include fewer or no AF episodes and less need for rhythm drugs in many people, particularly those with paroxysmal AF and troublesome symptoms. A proportion have recurrence and need a repeat procedure or continued medication. Risks include bleeding at the groin, fluid around the heart, stroke, injury to nearby structures and, rarely, serious complications that are explained at consent.

NICE NG196 recommends that people with AF are offered a choice of rate or rhythm control based on symptoms, and offers catheter ablation for those in whom drug treatment has been unsuccessful, is unsuitable or is not tolerated, and for selected people with AF and heart failure with reduced ejection fraction. It also emphasises that stroke risk assessment and anticoagulation decisions are made independently of the chosen strategy.

The cardiology team also considers AF type (paroxysmal or persistent), age, symptoms, size of the left atrium and other conditions. Shared decision-making, with realistic discussion of success rates and risks, is central.

• Minimal symptoms and AF has been present a long time: rate control is often acceptable.

• Symptoms limit life despite tablets, or tablets are not tolerated: ask whether ablation is appropriate.

• AF with heart failure: discuss ablation, as it may be recommended in selected cases.

• Young and keen to avoid lifelong drugs: discuss both options, noting that ablation may need repeating.

• Fainting, chest pain, severe breathlessness or stroke symptoms: call 999.

Ablation is not a guaranteed cure, and having it does not automatically allow you to stop blood thinners. And rate control is not "doing nothing"; it is a legitimate treatment strategy. Also, AF that is symptom-free still raises stroke risk and needs assessment.

Lifestyle changes matter too: alcohol, weight, sleep apnoea and blood pressure all influence AF burden and the success of treatment.